Current computational tools for de novo ligand design

Current Opinion in Biotechnology

Volumn 7, Issue 4, 1996, Pages 433-436

  Böhm, Hans Joachim ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND;

ALGORITHM; CHEMICAL STRUCTURE; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN BINDING; SHORT SURVEY;

EID: 0030220147     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(96)80120-0     Document Type: Article

References (61)

1. Navia MA, Murcko MA. Use of structural information in drug design. Curr Opin Struct Biol. 2:1992;202-210.
2. Greer J, Erickson JW, Baldwin JJ, Varney MD. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem. 37:1994;1035-1054.
3. Verlinde CLMJ, Hol WGJ. Structure-based drug design: progress, results and challenges. Structure. 2:1994;577-587.
4. Mack H, Pfeiffer T, Hornberger W, Böhm HJ, Höffken HW. Design, synthesis and biological activity of novel rigid amidinophenylalanine derivatives as inhibitors of thrombin. J Enzym Inhib. 9:1995;73-86.
5. Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE, Hartley LW, Jones ND, Mihelich ED. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 2:1995;458-465.
6. Thaisrivongs S, Watenpaugh KD, Howe WJ, Tomich PK, Dolak LA, Chong KT, Tomich CC, Tomasselli AG, Turner SR, Strohbach JW. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors. J Med Chem. 38:1995;3624-3637.
7. Von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Phan TV, Smythe ML, White HF, Oliver SW, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
8. Baldwin JJ, Ponticello GS, Anderson PS, Christy ME, Murcko MA, Randall WC, Schwam H, Sugrue MF, Springer JP, Gautheron P, et al. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem. 32:1989;2510-2513.
9. Vara Prasad JVN, Para KS, Lunney EA, Ortwine DF, Dunbar JB, Ferguson D, Tummino PJ, Hupe D, Tait BD, Domagala JM, Humblet C, et al. Novel series of archiral, low molecular weight, and potent HIV-1 protease inhibitors. J Am Chem Soc. 116:1994;6989-6990.
10. Lam PYS, Jadhav PK, Eyermann CJ, Hodge CN, Ru Y, Bacheler LT, Meek JL, Otto MJ, Rayner MM, Wong YN, et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 262:1994;380-384.
11. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, Labler L, Müller K, Schmid G, Tschopp TB, Van de Waterbeemd H. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem. 37:1994;3889-3901.
12. Edwards PD, Andisik DW, Strimpler AM, Gomes B, Tuthill PA. Nonpeptidic inhibitors of human neutrophil elastase. 7. Design, synthesis, and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones. of special interest J Med Chem. 39:1996;1112-1124 The latest paper in an exceptional series of publications describing the structure-based design of elastase inhibitors leading to highly active and orally available compounds.
13. Obst U, Gramlich V, Diederich F, Weber L, Banner DW. Design of novel nonpetidic thrombin inhibitors and structure of a thrombin - inhibitor complex. Int Ed Angew Chem. 107:1995;1874-1877.
14. Anonymous Dorzolamide hydrochloride. Drugs, News & Perspectives. 8:1995;237.
15. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem. 28:1985;849-857.
16. Boobbyer DNA, Goodford PJ, McWhinnie PM, Wade RC. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem. 32:1989;1083-1094.
17. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins. 11:1991;29-34.
18. Kuntz ID, Meng EC, Shoichet BK. Structure-based molecular design. Accounts Chem Res. 27:1994;117-123.
19. Martin YC. 3D database searching in drug design. J Med Chem. 35:1992;2145-2154.
20. Böhm HJ. Ligand design. Kubinyi H. 3D QSAR in Drug Design. 1993;386-405 Escom, Leiden.
21. Lewis RA, Leach A. Current methods for site-directed structure generation. J Comput Aided Mol Des. 8:1994;467-475.
22. Blaney JM, Dixon JS. A good ligand is hard to find: automated docking methods. Perspect Drug Discov Des. 1:1993;301-319.
23. Böhm HJ. Site-directed structure generation by fragment-joining. Perspect Drug Discov Des. 3:1995;21-33.
24. Kuntz ID. Structure-based strategies for drug design and discovery. Science. 257:1992;1078-1082.
25. DesJarlais RL, Sheridan RP, Seibel GL, Dixon JS, Kuntz ID, Venkataraghavan R. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J Med Chem. 31:1988;722-729.
26. Moon JB, Howe WJ. Computer design of bioactive molecules: a method for receptor-based de novo ligand design. Proteins. 11:1991;314-328.
27. Nishibata Y, Itai A. Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron. 47:1991;8985-8990.
28. Nishibata Y, Itai A. Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. J Med Chem. 36:1993;2921-2928.
29. Böhm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 6:1992;61-78.
30. Böhm HJ. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des. 6:1992;593-606.
31. Bohacek RS, McMartin C. Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J Am Chem Soc. 116:1994;5560-5571.
32. Caflish A, Karplus M. Computational combinatorial chemistry for de novo ligand design: review and assessment. Perspect Drug Discov Des. 3:1995;51-84.
33. Tschinke V, Cohen NC. The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. J Med Chem. 36:1993;3863-3870.
34. Mata P, Gillet VJ, Johnson P, Lampreia J, Myatt GJ, Sike S, Stebbings AL. SPROUT: 3D structure generation using templates. J Chem Inform Comput Sci. 35:1995;479-493.
35. Roe DC, Kuntz ID. Builder v.2: improving the chemistry of a de novo design strategy. J Comput Aided Mol Des. 9:1995;269-282.
36. Gehlhaar DK, Moerder KE, Zichi D, Sherman CJ, Ogden RC, Freer ST. De novo design of enzyme inhibitors by Monte Carlo ligand generation. of special interest J Med Chem. 38:1995;466-472 This paper is a description of a novel computer program for de novo ligand design. The method was used to guide improvements to HIV protease inhibitors. One such improvement resulted in a compound selected for preclinical studies as an antiviral agent against AIDS.
37. Babine RE, Bleckman TM, Kissinger CR, Showalter R, Pelletier LA, Lewis C, Tucker C, Moomaw E, Parge HE, Villafranca JE. Design, synthesis and X-ray crystallographic studies of noval FKBP-12 ligands. Bioorg Med Chem Lett. 5:1995;1719-1724.
38. Pisabarro MT, Ortiz AR, Palomer A, Cabre F, Garcia L, Mauleon D, Carganico G. Rational modification of human synovial fluid phospholipase A2 inhibitors. J Med Chem. 37:1994;337-341.
39. Shoichet BK, Stroud RM, Santi DV, Kuntz ID, Perry KM. Structure-based discovery of inhibitors of thymidylate synthase. Science. 259:1993;1445-1450.
40. Ring CS, Sun E, McKerrow JH, Lee GK, Rosenthal PJ, Kuntz ID, Cohen FE. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci USA. 90:1993;3583-3587.
41. Böhm HJ. On the use of LUDI to search the find chemicals directory for ligands of proteins of known three-dimensional structure. J Comput Aided Mol Des. 8:1994;623-632.
42. Meyer EF, Botos I, Scapozza L, Zhang D. Backward binding and other structural surprises. Perspect Drug Discov Des. 3:1995;168-195.
43. Oshiro CM, Kuntz ID, Dixon JS. Flexible ligand docking using a genetic algorithm. J Comput Aided Mol Des. 9:1995;113-130.
44. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of solvation. J Mol Biol. 245:1995;43-53.
45. Rarey M, Wefing S, Lengauer T. Placement of meidum-sized fragments into active sites of proteins. J Comput Aided Mol Des. 10:1996;41-54.
46. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Freer ST. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. of special interest Chem Biol. 2:1995;317-324 A very fast docking program using a very simple scoring function.
47. Gerber PR, Müller K. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J Comput Aided Mol Des. 9:1995;251-268.
48. Leach AR. Ligand docking to proteins with discrete side-chain flexibility. J Mol Biol. 235:1994;345-356.
49. Van Gunsteren WF, Weiner PK. Computer Simulations of Biomolecular Systems. 1989;Escom, Leiden.
50. Böhm HJ, Klebe G. What can we learn from molecular recognition in protein - ligand complexes for the design of new drugs? Int Ed Angew Chem. 108:1996;. in press.
51. Ajay, Murcko MA. Computational methods to predict binding free energy in ligand - receptor complexes. of outstanding interest J Med Chem. 38:1995;4953-4967 An excellent review that points out the major current challenges for the development of new scoring functions.
52. Bohacek RS, McMartin C. Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high resolution graphical tool for drug design. J Med Chem. 35:1992;1671-1684.
53. Böhm HJ. The development of a simple empirical scoring function to estimate the binding constant for a protein - ligand complex of known three-dimensional structure. J Comput Aided Mol Des. 8:1994;243-256.
54. Horton N, Lewis M. Calculation of the free energy of association for protein complexes. Protein Sci. 1:1992;169-181.
55. Krystek S, Stouch T, Novotny J. Affinity and specificity of serine endopeptidase - protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures. J Mol Biol. 234:1993;661-679.
56. Vajda S, Weng Z, Rosenfeld R, DeLisi C. Effect of conformational flexibility and solvation on receptor - ligand binding free energies. Biochemistry. 33:1994;13977-13988.
57. Holloway MK, Wai JM, Halgren TA. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem. 38:1995;305-317.
58. Grootenhuis PDJ, Van Galen PJM. Correlation of binding affinities with non-bonded interaction energies of thrombin - inhibitor complexes. Acta Crystallogr D - Biol Crystallogr. 51:1995;560-566.
59. Wang H, Ben-Naim A. A possible invovement of solvent-induced interactions in drug design. J Med Chem. 39:1996;1531-1539.
60. Mikol V, Papgeorgiou C, Borer X. The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A. of special interest J Med Chem. 38:1995;3361-3367 A very interesting paper highlighting the importance of water molecules in protein - ligand interactions.
61. Morton A, Matthews BW. Specificity of ligand binding in a buried nonpolar cavity of T4 lysozyme: linkage of dynamics and structural plasticity. of special interest Biochemistry. 34:1995;8576-8588 This paper describes the binding of several small molecules to a T4 lysozyme mutant. This type of experimental data is most important to calibrate new computational methods for docking and de novo ligand design.